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Background  :  Weight  loss  is  common  in  patients  with  chronic  obstructive  pulmonary  disease  (COPD).  However,  the 
mechanisms  of  this  weight  loss  are  still  unclear. 
Methods  :  Sixty  male  patients  with  stable  COPD  and  45  healthy  male  controls  participated  in  this  study.  The  COPD 
patients  were  divided  into  two  groups,  that  is,  the  emphysema  and  chronic  bronchitis  groups,  by  the  transfer  coefficient 
of  carbon  monoxide.  The  body  composition,  resting  energy  expenditure  (REE),  plasma  leptin  levels  and  serum  tumor 
necrosis  factor-alpha  (TNF-α)  were  measured  in  all  the  study  participants.  The  difference  and  correlation  of  these 
parameters  were  investigated  between  the  two  groups. 
Results  :  Emphysematous  patients  were  characterized  by  a  lower  body  mass  index  (BMI)  and  fat-mass  (FM) 
compared  with  the  chronic  bronchitis  patients  (p<0.001).  The  plasma  leptin  levels,  as  corrected  for  the  FM,  were  not 
different  between  the  COPD  patients  and  healthy  controls  (78.3±30.9  pg/mL/kg  vs.  70.9±17.3  pg/mL/kg,  respectively), 
and  the  plasma  leptin  levels,  as  adjusted  for  the  FM,  were  also  not  different  between  the  two  groups  of  COPD 
patients.  In  the  chronic  bronchitis  patients,  the  plasma  leptin  concentration  was  correlated  with  the  BMI  (r=0.866, 
p<0.001)  but  it  was  not  correlated  with  the  BMI  in  the  emphysema  patients.  The  serum  TNF-α levels  were  higher  in 
the  stable  COPD  patients  than  those  in  the  controls,  but  there  was  no  statistical  difference  (10.7±18.6  pg/mL  vs. 
7.2×3.5  pg/mL,  respectively,  p0.05).  The  leptin  concentration  was  well  correlated  with  the  BMI  and  %FM  in  the  patients 
with  chronic  bronchitis  and  the  leptin  concentration  was  only  correlated  with  the  %FM  (r=0.450,  p=0.027)  in  emphysema 
patients.  There  was  no  correlation  between  the  plasma  leptin  concentration,  as  adjusted  for  the  fat  mass,  and  the 
activity  of  the  TNF-α system. 
Conclusion  :  The  interaction  of  leptin  and  the  activity  of  the  TNF-α system  in  the  pathogenesis  of  tissue  depletion 
may  not  play  an  important  role  in  chronic  stable  COPD  patients.
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INTRODUCTION
Weight  loss  in  patients  with  chronic  obstructive  pulmonary 
disease  (COPD)  is  considered  to  be  a  natural  course  of  the 
disease  and  it  is  understood  to  be  a  type  of  adaptation  process 
to  minimize  oxygen  consumption
1, 2).  However,  the  weight  loss  in 
COPD  patients  has  been  shown  to  be  an  independent  risk 
factor  for  reducing  the  capacity  to  perform  physical  activity  and 
to  influence  their  death  rate
3-5),  and  so  there  is  increasing 
interest  on  the  mechanism  of  this  weight  loss.
The  body  composition  of  COPD  patients  varies  according  to 
the  subtypes  of  disease.  It  has  been  reported  that  the  reduction 
of  body  fat  in  patients  with  emphysema  is  more  severe  than 
that  in  those  patients  with  chronic  bronchitis
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chronic  bronchitis  patients  appeared  to  maintain  their  weight  to 
some  degree,  the  fat-free  mass  may  actually  be  decreased.
Leptin  is  a  product  of  obesity  genes,  and  it  plays  an 
important  role  not  only  in  energy  metabolism,  but  also  in 
glucose  and  lipid  metabolism
7-10).  Leptin  production  is  acutely 
increased  in  pathologic  conditions  such  as  infection  or 
inflammation
11),  chronic  renal  insufficiency
12)  and  sepsis
13),  which 
causes  weight  loss  by  inducing  anorexia  and  hypermetabolism. 
In  animal  studies,  administration  of  inflammatory  cytokines 
that  induce  anorexia,  such  as  tumor  necrosis  factor-α (TNF-α) 
or  interleukin-1,  resulted  in  the  up-regulation  of  leptin  mRNA  in 
adipose  tissues  and  an  in  increase  of  the  serum  leptin 
concentration
12, 14, 15).  This  finding  suggests  that  leptin  is  not 
under  a  normal  regulation  mechanism  and  it  is  influenced  by 
inflammatory  mediators,  and  such  a  reaction  may  act  as  a 
mechanism  of  weight  loss.
We  evaluated  the  differences  of  body  composition  in  stable 
patient  with  COPD  and  we  also  assessed  the  plasma  leptin  and 
TNF-α  concentrations  in  clinically  stable  COPD  patients.  The 
aim  of  this  study  was  to  investigate  the  relationship  between  the 
plasma  leptin  concentration  and  the  activity  of  the  TNF-α 
system,  including  the  soluble  TNF  receptors  (sTNF-R55  and 
sTNF-R75),  in  those  patients.
MATERIALS AND METHODS
Study  population
Sixty  male  patients  with  stable  COPD  were  diagnosed 
according  to  the  criteria  of  the  American  Thoracic  Society
16). 
Their  irreversible  chronic  airflow  obstruction  was  confirmed  by 
performing  body  plethysmograpy.  The  patients  had  been 
clinically  stable  for  at  least  3  months  prior  to  the  study  and  they 
lacked  clinical  signs  of  exacerbation  such  as  the  increase  of 
sputum  production  or  purulence,  and  exacerbation  of  dyspnea. 
We  exclude  those  patients  who  had  conditions  known  to 
influence  the  leptin  or  TNF-α  levels  such  as  malignancy, 
infection,  cardiac  failure,  recent  surgery,  endocrine  disorders, 
collagen  vascular  disease  and  corticosteroid  use.
Pulmonary  function  was  measured  with  a  compute-assisted 
plethysmography  (Vmax  229,  Sensor  Medics,  Yorba  Linda, 
California,  U.S.A.).  The  highest  value  from  at  least  three 
maneuvers  was  used  and  the  lung  function  values  were 
expressed  as  a  percentage  of  the  normal  predicted  value.
Emphysema  was  differentiated  from  chronic  bronchitis  by  the 
clinical  findings  and  the  diffusion  capacity,  in  other  words,  the 
Kco  (transfer  coefficient  of  carbon  monoxide,  DLco/VA)  was 
applied
17).  Among  the  patients  with  findings  on  simple  chest 
X-ray  that  both  diaphragms  were  flat  or  with  the  depressed 
downward  pattern,  the  posterior  space  of  the  sternum  was 
dilated  and  there  was  reduced  contrast  of  the  local  or  systemic 
bronchitis-blood  vessels,  those  cases  with  a  kco  lower  than  60 
were  classified  as  having  emphysema,  and  among  the  patients 
with  increased  contrast  in  the  bronchitis-blood  vessels  seen  on 
chest  X-ray,  the  cases  with  a  Kco  higher  than  80  were 
classified  as  having  chronic  bronchitis
Among  the  60  male  subjects,  there  were  27  chronic  bronchitis 
patients  and  24  emphysema  patients.  9  patients  could  not  be 
classified  as  having  emphysema  or  chronic  bronchitis  because 
their  kco  values  were  60～79. 
Forty  five  age-matched  health  male  volunteers  were  studied 
as  control  subjects.  The  control  subjects  had  no  medical  illness 
and  they  had  normal  physical  examinations.  Their  complete 
blood  cell  counts  and  blood  chemistries  were  normal.  They 
showed  no  symptoms  or  signs  of  infection  at  the  time  of  this 
study. 
Body  composition  analysis
Body  weight  and  height  were  measured  for  all  subjects  after 
an  overnight  fast.  Body  composition  analysis  was  performed  by 
applying  the  bioelectrical  impedance  method  with  using  an 
instrument  and  software  made  by  the  Medigate  Cooperation 
(BCA-100,  Seoul,  Korea).  The  body  mass  index  (BMI),  fat  mass 
(FM),  and  fat-free  mass  (FFM)  were  then  calculated.
Measurement  of  resting  energy  expenditure
Resting  energy  expenditure  (REE)  was  measured  by  an 
open-circuit  indirect  calorimetry  system  with  using  a  ventilated 
hood  (Sensor  Medics  Vmax  229,  Yorba  Linda,  California, 
U.S.A.).  The  measurements  of  REE  were  performed  at  6  a.m. 
with  the  patients  awake  and  in  a  comfortable  supine  position. 
The  patients  were  in  a  fasting  state  from  9  p.m.  the  previous 
day  and  they  rested  about  30  minutes  prior  to  the 
measurement.  The  head  of  the  patient  was  covered  with  a 
canopy  (Beckman  Canopy  System,  Anheim,  California,  U.S.A.) 
and  the  leakage  of  air  to  outside  of  the  canopy  was  prevented. 
The  REE  was  only  measured  from  the  steady  state.  Steady 
states  were  defined  as  intervals  of  time  (a  minimum  of  5min) 
during  which  the  average  oxygen  consumption  and  carbon 
dioxide  production  changed  by  less  than  10%  and  5%, 
respectively.  The  REE  was  calculated  from  the  oxygen 
consumption  and  carbon  dioxide  production  with  using  Weir's 
formula.  The  expected  value  of  the  REE  was  obtained  by  the 
HarrisBenedict  equation. 
Measurement  of  plasma  leptin
For  all  subjects,  blood  was  drawn  between  8:00  and  9:00 
a.m.  by  venipuncture  after  fasting  since  9:00  p.m.  the  previous 
night.  Both  the  serum  and  plasma  were  separated  from  the 
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COPD Healthy  subjects p-value
(n=60) (n=45)
Age,  years 63.6±7.4 66.5±8.9 NS 
BMI,  kg/m
2 21.9±3.0 24.7±2.6 0.039
FM,  % 16.7±8.8 23.9±7.1 0.000
FFM,  % 89.7±6.2 73.4±8.4 0.000
FVC,  %  pred 79.0±16.2 109.6±11.1 0.000
FEV1,  %  pred 57.0±17.0 97.3±13.2 0.000
TLC,  %  pred 130.4±42.5 106.2±36.9 0.000
REE,  %  pred 105.5±14.2 98.7±20.1 NS
Values  are  means±SDs.  BMI,  body  mass  index;  FM,  fat  mass;  FFM,  fat-free  mass;  FVC,  forced  vital  capacity;  FEV1,  forced 
expiratory  volume  in  one  second;  TLC,  total  lung  capacity;  REE,  resting  energy  expenditure. 
Table  1.  Characteristics  of  the  study  patients  with  chronic  obstructive  pulmonary  disease  and  the  healthy  subjects
COPD Healthy  subjects p-value
(n=60) (n=45)
Leptin,  pg/mL 1086.0±443.9 1598.2±312.2 0.000
Leptin/FM,  pg/mL/kg 78.3±30.9 70.9±17.3 NS
TNF-α,  pg/mL 8.5±3.1 7.2±3.5 NS
sTNF-R55,  pg/mL 873.6±112.7 569.4±98.7 0.000
sTNF-R75,  pg/mL 854.0±124.9 532.8±106.1 0.000
Values  are  means±SDs.  TNF-α,  tumor  necrosis  factor-α;  sTNF-R55,  soluble  tumor  necrosis  factor  receptor  55;  sTNF-R75,  soluble 
tumor  necrosis  factor  receptor  75.
Table 2. Concentration of serum leptin, tumor necrosis factor-α, plasma sTNF-R55 and sTNF-R75 in patients with chronic obstructive pulmonary 
disease  and  the  healthy  subjects
samples  were  stored  at  -70℃ until  they  were  analyzed.
The  serum  leptin  levels  were  measured  by  a  highly  sensitive 
human  leptin  RIA  kit  (Linco  Res,  Inc.,  St.  Louis,  MO,  U.S.A.). 
 
Measurement  of  the  TNF-α,  TNF-R55,  and  TNF-R75 
levels
The  TNF-α and  its  receptor  (TNF-R55  and  TNF-R75)  levels 
were  determined  in  the  serum  with  using  a  duplicate  enzyme- 
linked  immunosorbent  assay  (ELISA)  kit  (Quantikine;  R  &  D 
system,  Minneapolis,  MN,  U.S.A.).  The  color  generated  was 
determined  with  using  a  spectrophotometric  microtiter  plate 
reader  (Model  450;  Bio-Rad,  Richmond,  California,  U.S.A.)  by 
measuring  the  optical  density  at  490  nm  and  450  nm  for  the 
TNF-α  and  TNF-receptors  (sTNF-R55  and  sTNF-R75), 
respectively.
Statistical  analysis   
The  results  are  given  as  means±standard  errors.  Statistical 
analysis  was  performed  with  the  Mann-Whitney  U-test  for  the 
nonparametric  data  to  analyze  differences  between  the  two 
study  groups.  The  relations  between  the  continuous  variables 
were  evaluated  with  Spearman's  rank  correlation  technique. 
Significance  was  determined  at  the  5%  level.  Multiple  linear 
stepwise  regression  analysis  was  performed  to  assess  the 
factors  that  may  influence  the  serum  leptin  concentration. 
Statistical  analysis  was  done  with  the  statistical  package  for 
social  science  (SPSS). 
RESULTS
The  clinical  and  demographic  characteristics  of  the  COPD 
patients  and  healthy  controls  are  shown  in  Table  1.  The  COPD 
patients  had  a  significantly  lower  BMI,  percent  of  body  FM  and 
percent  of  FFM  than  did  the  control  subjects,  whereas  no 
difference  was  seen  for  the  resting  energy  metabolism,  which 
was  expressed  as  a  percentage  of  the  predicted  value  (%REE). 
The  patients  with  COPD  had  moderate  to  severe  airflow 
limitation  (GOLD  I  or  II),  but  the  healthy  subjects  had  normal 
pulmonary  function.
We  analyzed  the  plasma  leptin  level  and  the  activity  of  the 
TNF-α system,  including  the  sTNF-R55  and  sTNF-R75,  in  the 
COPD  patients  and  the  healthy  subjects  (Table  2).  The  plasma 
leptin  levels  were  significantly  lower  in  the  patients  with  stable 
COPD  than  those  in  the  healthy  controls  (1086±443.9  pg/mL  vs. 
1598.2±312.2  pg/mL,  respectively,  p<0.001).  The  plasma  leptin 
levels  that  were  corrected  for  the  FM  were  not  different  between 
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Emphysema Chronic  Bronchitis p-value
(n=24) (n=27) 
Age,  year 62.2±7.1 64.8±7.0 NS
Body  weight,  kg 53.2±5.7 63.8±10.4 0.000
BMI,  kg/m
2  19.6±1.5 23.9±2.8 0.000
FM,  % 9.1±3.3 22.9±7.6 0.000
FFM,  % 94.8±2.0 85.2±5.7 0.000
FVC,  %  pred 82.9±16.4 77.6±15.8 NS
FEV1,  %  pred 57.5±17.8 61.6±16.4 NS
TLC,  %  pred 159.4±62.1 122.2±31.1 NS
RV,  %  pred 247.6±139.6 174.0±82.0 NS
Kco,  %  pred 44.4±9.6 101.3±19.8 0.013
REE,  %  pred 114.0±20.2 101.8±11.1 0.04
REE/FFM,  Kcal/Kg 29.2±6.9 27.6±3.9 NS
Values  are  means±SDs.  RV,  residual  volume;  Kco,  transfer  coefficient  of  carbon  monoxide;  BMI,  body  mass  index;  FM,  fat  mass; 
FFM,  fat-free  mass;  FVC,  forced  vital  capacity;  FEV1,  forced  expiratory  volume  in  one  second;  TLC,  total  lung  capacity;  REE, 
resting  energy  expenditure. 
Table  3.  Characteristics  of  the  patients  with  emphysema  or  chronic  bronchitis
Emphysema Chronic  bronchitis p-value
(n=24) (n=27)
Leptin,  pg/mL 662.2±311.0 1393.9±254.2 0.000
Leptin/FM,  pg/mL/kg 133.3±53.4 115.0±37.2 NS
TNF-α,  pg/mL 8.4±3.2 9.1±3.4 NS
sTNF-R55,  pg/mL 857.6±95.9 891±122.6 NS
sTNF-R75,  pg/mL 831.2±128.7 883.6±129.6 NS
Values  are  means±SDs.  TNF-α,  tumor  necrosis  factor-α;  sTNF-R55,  soluble  tumor  necrosis  factor  receptor  55;  sTNF-R75,  soluble 
tumor  necrosis  factor  receptor  75. 
Table 4. Concentration of serum leptin, tumor necrosis factor-α, plasma sTNF-R55 and sTNF-R75 in patients with emphysema or chronic 
bronchitis
pg/mL/kg  vs  70.9±17.3  pg/mL/kg,  respectively,  p>0.05). 
The  plasma  leptin  concentration  in  the  chronic  bronchitis 
patients  was  significantly  higher  than  that  in  the  emphysema 
patients.  However,  there  was  no  difference  after  adjustment  for 
FM  (Table  4).  We  found  a  significant  correlation  between  the 
plasma  leptin  concentration  and  the  BMI  in  the  chronic 
bronchitis  patients  (r=0.866,  p<0.001),  but  there  was  no  such 
correlation  in  the  emphysema  patients. 
Although  the  serum  TNF-α levels  were  higher  in  the  stable 
COPD  patients  than  those  in  the  controls,  this  difference  was 
not  statistically  significant  (8.5±3.1  pg/mL  vs.  7.2±3.5  pg/mL, 
respectively,  p>0.05).  However,  the  sTNF-R55  and  sTNF-R75 
levels  in  the  stable  COPD  patients  were  significantly  higher  than 
those  in  the  healthy  subjects  (p<0.001).
The  characteristics  of  the  COPD  subtypes  in  the  27  patients 
with  chronic  bronchitis  and  the  24  patients  with  emphysema  are 
presented  in  Table  3.  For  the  patients  with  chronic  bronchitis 
and  emphysema,  the  FVC,  FEV1,  total  lung  capacity  and 
residual  volume  were  not  different.  Nonetheless,  the  difference 
of  body  composition  between  the  two  diseases  was  distinct.  The 
BMI  of  the  emphysema  patients  was  significantly  lower  than  that 
of  the  patients  with  chronic  bronchitis  (p<0.001).  However,  the 
FM,  which  was  expressed  as  a  percentage  of  the  total  body 
weight  (%FM),  was  significantly  higher  for  the  patients  with 
chronic  bronchitis.  This  suggests  that  tissue  depletion  is  more 
severe  in  emphysema  patients. 
The  REE,  which  was  expressed  as  a  percentage  of  the 
predicted  value,  was  higher  for  the  patients  with  emphysema 
that  for  the  patients  with  chronic  bronchitis  (p<0.05).  However, 
there  was  no  difference  of  the  REE  adjusted  for  the  FFM 
(REE/FFM),  which  is  the  biologically  active  component,  between 
the  two  subtypes  of  COPD.
The  plasma  TNF-α  levels  were  higher  in  the  chronic 
bronchitis  patients  than  in  the  emphysema  patients  (9.1±3.4 
pg/mL  vs  8.4±3.2  pg/mL,  respectively)  but  the  difference  was 
not  statistically  significant.  The  sTNF-R55  and  sTNF-R75  levels 
were  not  different  between  the  two  subgroups  of  COPD  (p>0.05) 
(Table  4). 
First,  we  investigated  the  relationships  between  the  plasma 
leptin  concentration  and  body  composition  (Table  5).  The  leptin 
concentration  was  well  correlated  with  the  BMI  and  %FM  of  the 
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    Plasma  leptin 
COPD Emphysema Chronic  Bronchitis 
(n=60) (n=24) (n=27)
BMI,  kg/m
2 r=0.779 NS r=0.856
p=0.000 p=0.000
FM,  % r=0.806 r=0.450 r=0.767
p=0.000 p=0.027 p=0.000
REE,  %  pred NS NS NS
REE/FFM,  Kcal/Kg NS NS NS
BMI,  body  mass  index;  FFM,  fat-free  mass;  FM,  fat  mass;  REE,  resting  energy  expenditure
Table  5.  Correlations  between  the  plasma  leptin  concentration  and  the  body  mass  index  and  the  resting  energy  expenditure  in  patients 
with  chronic  obstructive  pulmonary  disease
Plasma  leptin 
COPD Emphysema Chronic  Bronchitis
(n=60) (n=24) (n=27)
TNF-α,  pg/mL NS NS NS
sTNF-R55,  pg/mL NS NS NS
sTNF-R75,  pg/mL NS NS NS
TNF-α,  tumor  necrosis  factor-α;  sTNF-R55,  soluble  tumor  necrosis  factor  receptor  55;  sTNF-R75,  soluble  tumor  necrosis  factor 
receptor  75
Table 6. Correlation analysis to elucidate the regulation of plasma leptin, as adjusted for the fat-mass, in patients with chronic obstructive 
pulmonarydisease 
correlations  between  the  plasma  leptin  concentration  and  BMI  in 
the  emphysema  patients.  However,  the  plasma  leptin  level  was 
correlated  with  the  %FM  (r=0.450,  p=0.027). 
Second,  we  analyzed  the  plasma  leptin  concentrations  and 
the  serum  TNF-α and  the  sTNF-R55  and  R-75  levels  in  the 
patients  with  COPD  (Table  6).  There  was  no  correlation 
between  the  plasma  leptin  concentration  that  was  adjusted  for 
the  fat  mass  and  the  serum  sTNF-R55  and  R-75  levels  in  the 
COPD  patients,  including  the  emphysema  and  chronic  bronchitis 
patients.  The  TNF-α  levels  were  not  correlated  with  any 
components  of  the  body  composition  in  the  COPD  patients 
(data  were  not  shown).
DISCUSSION
Until  now,  nutritional  aspects  such  as  the  reduction  of  food 
intake,  the  impairment  of  amino  acid  metabolism  and  the 
increased  energy  metabolism  have  been  considered  to  be 
important  causes  of  tissue  depletion  in  COPD  patients
1, 17-19). 
We  assessed  the  body  composition  and  the  tissue  depletion  in 
patients  with  COPD.  The  purpose  of  this  study  was  to 
determine  the  role  of  plasma  leptin  and  the  effect  of  the  pro- 
inflammatory  cytokine  TNF-α system  as  a  mechanism  related  to 
the  tissue  depletion  and  energy  metabolism  in  clinically  stable 
COPD  patients.
In  our  study,  the  COPD  patients  showed  significant  tissue 
depletion  compared  to  the  healthy  controls.  Weight  loss  was 
severe  in  the  emphysema  patients.  However,  the  pattern  of 
tissue  depletion  was  distinctly  different  according  to  the 
subtypes  of  COPD.  The  patients  with  emphysema  have  less 
body  fat  and  this  is  composed  of  mostly  FFM,  whereas  the 
body  fat  is  relatively  high  in  chronic  bronchitis  patients. 
Especially,  there  was  no  difference  in  BMI  between  chronic 
bronchitis  patients  and  the  healthy  controls.  Similar  results  have 
been  reported  by  Engelen
6)  and  Schols
2, 20).  These  different 
wasting  patterns  suggest  that  diverse  mechanisms  may  be 
involved  in  the  pathogenesis  of  weight  loss  in  COPD  patients.
The  mechanisms  of  weight  loss  in  COPD  patients  are  still 
unclear.  Both  anorexia  and  excessive  energy  expenditure  play  a 
role  in  the  weight-losing  associated  with  chronic  wasting 
diseases
1).  Leptin  is  a  pleiotrophic  hormone  that  plays  an 
important  role  in  the  regulation  of  food  intake  and  energy 
homeostasis
9, 10).  In  previous  studies,  the  plasma  leptin  levels 
were  significantly  lower  in  the  patients  with  COPD,  and 
especially  in  those  patients  who  were  losing  weight  or  who  had 
a  mal-nourished  status,  than  the  plasma  leptin  levels  in  the 
healthy  controls
20, 21).  In  another  study,  there  was  no  difference 
in  the  concentrations  of  plasma  leptin  between  the  COPD 
patients  without  weight  loss  and  who  had  clinically  stable 
disease  and  those  COPD  patients  with  acute  exacerbation
22, 23). 
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corrected  for  fat  mass  were  not  different  between  the  chronic 
stable  COPD  patients  and  the  healthy  controls,  and  plasma 
leptin  concentrations  were  correlated  with  nutritional  aspects. 
Because  of  their  significant  differences  in  fat-mass,  the 
difference  in  the  plasma  leptin  concentrations  between  the 
emphysema  and  chronic  bronchitis  patients  could  be  easily 
explained.  The  positive  correlation  between  plasma  leptin  and 
the  BMI  or  FM  in  chronic  stable  COPD  patients  demonstrates 
that  the  plasma  leptin  concentrations  remain  controlled  in  stable 
COPD  patients. 
Some  investigators  postulate  that  hypermetabolism  plays  a 
role  in  the  wasting  associated  with  COPD.  In  COPD,  the  resting 
energy  expenditure  and/or  daily  energy  expenditure  may  be 
elevated
24, 25).  The  suggested  mechanisms  for  hypermetabolism 
are  the  increased  oxygen  cost  of  breathing  and  the  decreased 
mechanical  efficacy  during  exercise
26).  Schols  and  colleagues
20) 
searched  for  the  resting  energy  expenditure  in  COPD  patients 
and  they  found  that  the  resting  energy  expenditure  was  not 
different  in  the  subtypes  of  COPD  patients.  Our  results  are 
concordant  with  that  previous  study.  In  our  study,  the  %REE 
was  higher  in  the  patients  with  emphysema  than  that  in  the 
chronic  bronchitis  patients.  However,  if  corrected  for  the  FFM 
which  is  the  biological  active  determinant  of  the  REE,  no 
difference  was  noted  between  the  two  subtypes  of  COPD. 
These  findings  are  contrary  to  other  studies
21, 22).  In  clinically 
stable  patients  with  COPD,  we  were  unable  to  find  a 
relationship  between  hypermetabloism  and  weight  loss. 
It  has  been  reported  that  the  activity  of  the  TNF-α system 
was  significantly  higher  in  the  bronchial  biopsies
27)  and  induced 
sputum
28)  of  COPD  patients.  In  addition,  increased  TNF-α levels 
were  demonstrated  by  Takabatake
21, 29)  and  Di  Francia
30)  in 
weight-losing,  stable  COPD  patients.  TNF-α is  considered  as  a 
marker  of  systemic  inflammatory  reaction.  There  have  been 
contradictory  results  of  the  TNF-α system  in  the  pathogenesis 
of  tissue  depletion  in  COPD  patients.  Elevated  plasma  TNF-α 
levels  were  reported  by  some  investigators  in  clinically  stable 
COPD  patients
21)  but  not  by  other  researchers,  or  these 
elevated  plasma  TNF-α  levels  were  found  only  in  the 
weight-losing
30)  or  hypoxemic  patients
33).  In  our  study,  the 
activity  of  the  TNF-α system,  including  TNF-R55  or  TNF-R75, 
was  found  to  be  significantly  elevated  in  the  clinically  stable 
COPD  patients,  as  compared  to  healthy  controls.  However, 
there  was  no  difference  in  the  activity  of  the  TNF-α  system 
between  the  emphysema  and  chronic  bronchitis  patients.  These 
results  suggest  that  the  activity  of  the  TNF-α system  may  not 
involved  with  weight-lost  in  patients  with  stable  COPD.
Experimental  animal
14, 15)  and  human
34)  studies  have  provided 
evidence  for  a  link  between  leptin  and  proinflammatory 
cytokines.  TNF-α  and  IL-1  treatment  of  fasted  hamsters 
increased  the  concentration  of  leptin  in  circulation  and  the  leptin 
messenger  RNA  in  adipose  tissue
14).  Zumbach  and  coworkers
34) 
reported  that  administration  of  endotoxin  or  cytokines  such  as 
TNF-α  or  IL-1  produced  a  prompt  and  dose-dependent 
increase  in  the  serum  leptin  levels  in  humans.  In  this  study, 
although  the  plasma  leptin  levels  were  significantly  higher  in 
chronic  bronchitis  patients,  the  levels  of  plasma  leptin  levels 
corrected  for  fat-mass  were  not  different  between  the 
emphysema  and  chronic  bronchitis  patients.  Furthermore,  we 
could  not  find  any  relationship  between  the  plasma  leptin 
concentration  and  the  activity  of  the  TNF-α system.  However, 
there  was  positive  correlation  between  the  plasma  leptin 
concentration  and  the  BMI  and  FM.  This  correlation  was 
stronger  in  patients  with  chronic  bronchitis.  These  findings 
suggest  that  the  plasma  leptin  concentration  was  primarily 
affected  by  the  body  composition,  the  BMI  or  the  FM,  rather 
than  by  the  activity  of  the  TNF-α  system.  In  clinically  stable 
COPD  patients,  the  physiologic  regulation  mechanism  of  leptin 
was  maintained  normally  in  the  condition  with  weight  loss.  In 
previous  studies,  any  relationship  between  the  plasma  leptin 
concentration  and  the  activation  of  the  TNF-α system  as  related 
to  systemic  inflammation  was  contradictory.  Some  authors,  but 
not  others,  have  reported  the  positive  correlation  between  the 
plasma  leptin  level  and  the  TNF-α  system  in  clinically  stable 
COPD  patients.
  In  summary,  we  found  that  the  plasma  leptin  levels  were 
not  elevated  in  clinically  stable  COPD  patients  and  the  levels 
were    correlated  with  body  composition  parameters  such  as  the 
body  mass  index  and  the  fat-mass  in  weight  losing,  stable 
COPD  patients.  There  was  no  difference  in  the  activity  of  the 
TNF-α  system  between  the  emphysema  patient  and  relatively 
weight  losing,  chronic  bronchitis  patients.  Moreover,  there  was 
no  correlation  between  the  plasma  leptin  levels  and  the  TNF-α 
system. 
  In  conclusion,  the  normal  regulation  mechanism  of  leptin  is 
maintained  in  chronic  stable  COPD  patients.  The  interaction  of 
leptin  and  the  activity  of  the  TNF-α system  in  the  pathogenesis 
of  tissue  depletion  may  not  play  an  important  role  in  chronic 
stable  COPD  patients.
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